Halma plc (LON:HLMA), a UK-based group of safety, environmental and healthcare technology companies, announced on Monday an expansion of its healthcare portfolio with the acquisition of Rovers Medical Devices B.V., a Netherlands-based company specialising in sample collection devices for cervical cancer prevention and diagnostics.

The initial consideration for the acquisition amounts to EUR85m (about GBP73m) on a cash- and debt-free basis, with additional performance-based payments of up to EUR6m (approximately GBP5m).

Rovers' products, including the Cervex-Brush, are used in over 90 countries, primarily by medical diagnostic companies, laboratories and research institutes.

With unaudited revenue of EUR12.0m (around GBP10.3m) in 2023 and robust return on sales, Rovers strengthens Halma's position in the healthcare sector.

Rovers will operate as a standalone entity within Halma's Healthcare sector under its current management team.